表紙
市場調查報告書

疫苗受託製造的全球市場的預測:2019年∼2029年

Global Vaccine Contract Manufacturing Market Report 2019-2029

出版商 Visiongain Ltd 商品編碼 347364
出版日期 內容資訊 英文 217 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
疫苗受託製造的全球市場的預測:2019年∼2029年 Global Vaccine Contract Manufacturing Market Report 2019-2029
出版日期: 2019年04月02日內容資訊: 英文 217 Pages
簡介

本報告提供全球疫苗受託製造市場相關調查分析,收益與成長預測,市場佔有率,主要國家,主要企業,趨勢和SWOT分析等相關的系統性資訊。

第1章 報告概要

第2章 關於疫苗

  • 疫苗的歷史
  • 疫苗的結構
    • 人工免疫
  • 疫苗的種類
    • 減毒活病毒疫苗 (LAV)
    • 重組活病毒疫苗
    • 不活化疫苗
    • 類毒素疫苗
    • 次單元疫苗
    • 共軛疫苗
    • 重組次單元疫苗
    • DNA疫苗
    • 重組載體疫苗
    • 治療疫苗
  • 疫苗能預防的疾病
  • 疫苗市場成長
  • 技術、法法規的改善

第3章 疫苗製造技術

  • 疫苗技術趨勢的摘要
  • 疫苗製造的新基材
  • 下一代表現系統和媒介
  • 器具趨勢
  • 預填充式注射器 (藥液已填充注射器) 和疫苗
  • 冷凍乾燥與疫苗製造
  • 細胞培養基

第4章 全球疫苗製造市場

  • 全球疫苗製造市場概要
  • 全球疫苗市場預測
  • 全球疫苗市場:各二級市場
  • 疫苗市場成長促進疫苗製造的效率
  • 兒童用疫苗市場概要
  • 成人用預防疫苗市場概要
  • 流感疫苗市場概要
  • 治療疫苗市場概要

第5章 全球疫苗受託製造

  • 醫藥品、生物科技產業上外包
  • 醫藥品受託製造機關 (CMO)
  • 醫藥品受託製造市場:總收益的預測
  • 疫苗受託製造市場

第6章 疫苗受託製造市場:疫苗的各類型

  • 兒童用疫苗
  • 成人用疫苗
  • 流感疫苗
  • 治療疫苗

第7章 疫苗受託製造市場:各工作流程

  • 下游工程
  • 上游工程

第8章 主要國家的疫苗受託製造市場

  • 主要國家的疫苗受託製造市場
  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區

第9章 疫苗受託製造的主要企業

  • 疫苗受託製造的主要企業
  • Baxter BioPharma Solutions
  • Boehringer Ingelheim
  • Catalent
  • Charles River Laboratories
  • IDT Biologika GmbH
  • Lonza
  • Meridian Life Science
  • Sigma-Aldrich Fine Chemicals (SAFC) (Merck KGaA)
  • SynCo Bio Partners
  • AbbVie Contract Manufacturing
  • Evonik Degussa
  • Vetter Pharmaceutical
  • Pfizer CentreOne
  • Nipro

第10章 全球疫苗製造市場:世界市場趨勢

  • 疫苗受託製造業趨勢
  • SWOT分析

第11章 結論

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0383

Title:
Global Vaccine Contract Manufacturing Market Report 2019-2029
Paediatric Vaccines, Adult Vaccines, Influenza Vaccines, Therapeutic Vaccines, Downstream Processing, Fill & Finish Operations, Analytical & QC Studies, Packaging, Upstream Processing, Mammalian Expression Systems, Bacterial Expression Systems, Yeast Expression Systems, Baculovirus/Insect Expression Systems, Other Upstream Processing.

The global vaccine contract manufacturing market was worth $1.9bn in 2018 and is expected to grow at a CAGR of 9.3% from 2019-2023. In 2018, the paediatric vaccines segment held 48% of the global vaccine contract manufacturing market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 217-page report you will receive 80 tables and 57 figures - all unavailable elsewhere.

The 217-page report provides clear detailed insight into the global vaccine contract manufacturing market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Revenue and growth forecasts from 2019 to 2029 for the global vaccine market
  • Revenue and growth forecasts from 2019 to 2029 for the global vaccine contract manufacturing market

Revenue and growth forecasts from 2019 to 2029 for the global vaccine contract manufacturing market by type:

  • Paediatric Vaccines
  • Adult Vaccines
  • Influenza Vaccines
  • Therapeutic Vaccines

Revenue and growth forecasts from 2019 to 2029 for the global vaccine contract manufacturing market by workflow:

  • Downstream Processing: the revenues are further broken down into Fill & Finish Operations, Analytical & QC Studies, Packaging
  • Upstream Processing: the revenues are further broken down into Mammalian Expression Systems, Bacterial Expression Systems, Yeast Expression Systems, Baculovirus/Insect Expression Systems, Other Upstream Processing
  • Revenue and growth forecasts from 2019 to 2029 for the leading regional and national markets:
  • North America: the revenues are further broken down into the US and Canada
  • Europe: the revenues are further broken down into the UK, Germany, France, Italy and Spain
  • Asia-Pacific: the revenues are further broken down into China, Japan and India
  • Rest of the World: the revenues are further broken down into Brazil, Mexico, Russia and South Africa

The regional markets are further broken down by type and workflow.

Discussion and profiles of the leading players in the vaccine contract manufacturing market:

  • AbbVie
  • Baxter BioPharma Solutions
  • Boehringer Ingelheim
  • Catalent
  • Charles River Laboratories
  • Evonik Degusa
  • IDT Biologika
  • Lonza
  • Meridian Life Science
  • Nipro Corporation
  • Pfizer CentreOne
  • Sigma Aldrich Fine Chemicals
  • SynCo Bio Partners
  • Vetter Pharmaceutical

A SWOT analysis discussing the industry trends, strengths, weaknesses, opportunities and threats.

Discussion on vaccine manufacturing technologies covering new substrates for vaccine production, next-generation expression systems and vectors, equipment trends, pre-filled syringes and vaccines, lyophilization and vaccine manufacturing, cell-based techniques.

Key Questions Answered by this Report:

  • How is the vaccine contract manufacturing market evolving?
  • What is driving and restraining the vaccine contract manufacturing market?
  • What are the market shares of the leading segments of the vaccine contract manufacturing market in 2018?
  • What is the value of the leading sectors in important regions of the world?
  • What will be the main driver of the overall market from 2019 to 2029?
  • How will political and regulatory factors influence the regional markets and submarkets?
  • Will leading national vaccine contract manufacturing markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the leading national markets change by 2029 and which country will lead the market in 2029?
  • How will the industry evolve during the period between 2019 and 2029?

Visiongain's study is intended for anyone requiring commercial analyses for the global vaccine contract manufacturing market. You find data, trends and predictions.

Buy our report today Global Vaccine Contract Manufacturing Market Report 2019-2029: Paediatric Vaccines, Adult Vaccines, Influenza Vaccines, Therapeutic Vaccines, Downstream Processing, Fill & Finish Operations, Analytical & QC Studies, Packaging, Upstream Processing, Mammalian Expression Systems, Bacterial Expression Systems, Yeast Expression Systems, Baculovirus/Insect Expression Systems, Other Upstream Processing.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. World Vaccine Contract Manufacturing Market Highlights
  • 1.2. Why You Should Read This Report?
  • 1.3. How This Report Delivers
  • 1.4. Key Questions Answered by This Analytical Report
  • 1.5. Who is This Report For?
  • 1.6. Methodology
  • 1.7. Associated Visiongain Reports
  • 1.8. Frequently Asked Questions (FAQ)

2. Introduction to Vaccines

  • 2.1. The History of Vaccines
  • 2.2. How Do Vaccines Work?
    • 2.2.1. Artificial Immunity
  • 2.3. Types of Vaccine
    • 2.3.1. Live, Attenuated Vaccines (LAVs)
    • 2.3.2. Recombinant Live Vaccines
    • 2.3.3. Inactivated Vaccines
    • 2.3.4. Toxoid Vaccines
    • 2.3.5. Subunit Vaccines
    • 2.3.6. Conjugate Vaccines
    • 2.3.7. Recombinant Subunit Vaccines
    • 2.3.8. DNA Vaccines
    • 2.3.9. Recombinant Vector Vaccines
    • 2.3.10. Therapeutic Vaccines
  • 2.4. Diseases Preventable with Vaccines
  • 2.5. The Rise of the Vaccines Market
  • 2.6. Technological and Regulatory Improvements

3. Vaccine Manufacturing Technologies, 2018

  • 3.1. Summary of Vaccine Technology Trends
  • 3.2. New Substrates for Vaccine Production
    • 3.2.1. Shift towards Cell-Based Manufacturing Technology
    • 3.2.2. Benefits of Cell-Based Techniques
    • 3.2.3. Mammalian Cell Lines
      • 3.2.3.1. Madin Darby Canine Kidney Cells (MDCK)
      • 3.2.3.2. Vero Cells
      • 3.2.3.3. PerC6 Cells
    • 3.2.4. Avian-Derived Cell Lines
      • 3.2.4.1. EB66 Stem Cell Technology: Vivalis
    • 3.2.5. Plant-Based Vaccines
      • 3.2.5.1. Medicago's Proficia VLP Vaccine Technology
    • 3.2.6. Insect Egg-Based Production Systems
      • 3.2.6.1. Novavax
      • 3.2.6.2. Protein Sciences Corporation (PSC)
  • 3.3. Next-Generation Expression Systems and Vectors: Increasing Production Yield
    • 3.3.1. AdVac Technology: Crucell
    • 3.3.2. AdCEV Vectors: AfriVax
    • 3.3.3. Pfenex Expression Technology: Pfenex
  • 3.4. Equipment Trends
    • 3.4.1. The Shift Towards Disposable Single-use Equipment
    • 3.4.2. Bioreactors and Vaccine Production
      • 3.4.2.1. Single-Use Bioreactors
      • 3.4.2.2. Main Applications of Disposable Bioreactors
      • 3.4.2.3. Current Single-Use Bioreactor Systems in the Market
  • 3.5. Prefilled Syringes and Vaccines
    • 3.5.1. Growing Market for Pre-Filled Syringes
    • 3.5.2. Pre-Filled Vaccine Products
    • 3.5.3. Drivers and Restraints for Pre-Filled Syringes
    • 3.5.4. Product Stability and Quality Assurance Programme
      • 3.5.4.1. Paediatric H1N1 Vaccine
      • 3.5.4.2. Reported Challenges Flu Vaccines
      • 3.5.4.3. Novartis' Agriflu and Fluad Ban is Lifted
      • 3.5.4.4. Baxter Flu Vaccine and Side Effects
      • 3.5.4.5. Reported Shelf Life with H1N1 Vaccine
  • 3.6. Lyophilisation and Vaccine Manufacturing
    • 3.6.1. Lyophilisation of Vaccines Will Increase
  • 3.7. Cell Media Can Improve Virus Yield

4. The Global Vaccine Manufacturing Market 2019-2029

  • 4.1. Overview of the Global Vaccine Manufacturing Market 2019-2029
  • 4.2. World Vaccine Market Forecast 2019-2029
  • 4.3. The Global Vaccine Market by Submarket, 2018 and 2019
  • 4.4. Growth in Vaccine Market Will Drive Efficiency in Vaccine Manufacturing
  • 4.5. Paediatric Vaccines Market Overview
  • 4.6. Adult Prophylactic Vaccines Market Overview
  • 4.7. Influenza Vaccines Market Overview
  • 4.8. Therapeutic Vaccines Market Overview

5. The Global Vaccine Contract Manufacturing 2019-2029

  • 5.1. Outsourcing in the Pharmaceutical and Biotechnology Industry
    • 5.1.1. Reasons to Outsource
    • 5.1.2. Benefits of Outsourcing
    • 5.1.3. The Challenges in Outsourcing Vaccine Manufacturing
    • 5.1.4. Why Should Companies Outsource Vaccine Manufacturing?
    • 5.1.5. Strategic Outsourcing Vs Tactical Outsourcing
    • 5.1.6. Virtual Companies
  • 5.2. Contract Manufacturing Organisations (CMOs)
    • 5.2.1. Manufacturing Services Offered by CMOs
    • 5.2.2. Vaccine Manufacturing Activities Typically Outsourced
  • 5.3. The Vaccine Contract Manufacturing Market: Overall Revenue Forecast 2019-2029
  • 5.4. Contract Manufacturing Market for Vaccines 2018-2029
    • 5.4.1. Market Size for Contract Manufacturing of Vaccines 2018
    • 5.4.2. Vaccine Contract Manufacturing Market Forecast 2019-2029

6. Vaccine Contract Manufacturing Market by Vaccine Type, 2019-2029

  • 6.1. Paediatric Vaccines
  • 6.2. Adult Vaccines
  • 6.3. Influenza Vaccines
  • 6.4. Therapeutic Vaccines

7. Vaccine Contract Manufacturing Market by Workflow, 2019-2029

  • 7.1. Downstream Processing
    • 7.1.1. Fill & Finish Operations
    • 7.1.2. Analytical & QC Studies
    • 7.1.3. Packaging
  • 7.2. Upstream Processing
    • 7.2.1. Mammalian Expression Systems
    • 7.2.2. Bacterial Expression Systems
    • 7.2.3. Yeast Expression Systems
    • 7.2.4. Baculovirus/Insect Expression Systems
    • 7.2.5. Other Upstream Processing

8. Leading National Markets for Vaccine Contract Manufacturing, 2019-2029

  • 8.1. Leading National Markets for Vaccine Contract Manufacturing
  • 8.2. North America Vaccine Contract Manufacturing Market, 2018-2029
    • 8.2.1. US Vaccine Contract Manufacturing Market Forecast, 2018-2029
    • 8.2.2. Canada Vaccine Contract Manufacturing Market Forecast, 2018-2029
  • 8.3. The Europe Vaccine Contract Manufacturing Market, 2018-2029
    • 8.3.1. Germany Vaccine Contract Manufacturing Market, 2016-2028
    • 8.3.2. UK Vaccine Contract Manufacturing Market, 2018-2029
    • 8.3.3. French Vaccine Contract Manufacturing Market, 2018-2029
    • 8.3.4. Italy Vaccine Contract Manufacturing Market, 2018-2029
    • 8.3.5. Spain Vaccine Contract Manufacturing Market, 2018-2029
  • 8.4. Asia-Pacific Vaccine Contract Manufacturing Market, 2018-2029
    • 8.4.1. Japan Vaccine Contract Manufacturing Market, 2018-2029
    • 8.4.2. China Vaccine Contract Manufacturing Market, 2018-2029
    • 8.4.3. India Vaccine Contract Manufacturing Market, 2018-2029
  • 8.5. Rest of the World Vaccine Contract Manufacturing Market, 2018-2029
    • 8.5.1. Brazil Vaccine Contract Manufacturing Market, 2018-2029
    • 8.5.2. Mexico Vaccine Contract Manufacturing Market, 2018-2029
    • 8.5.3. Russia Vaccine Contract Manufacturing Market, 2018-2029
    • 8.5.4. South Africa Vaccine Contract Manufacturing Market, 2019-2029

9. Leading Vaccine Contract Manufacturing Companies, 2018-2029

  • 9.1. Leading Vaccine Contract Manufacturing Organisations
  • 9.2. Baxter BioPharma Solutions
    • 9.2.1. Recent Financial Performance
    • 9.2.2. Key Developments
  • 9.3. Boehringer Ingelheim
    • 9.3.1. Recent Financial Performance
    • 9.3.2. Ben Venue Laboratories
    • 9.3.3. Manufacturing Deals 2011-2017
  • 9.4. Catalent
    • 9.4.1. Recent Financial Performance
    • 9.4.2. Catalent: Financial Performance by Segment, 2011-2016
    • 9.4.3. Catalent Injectable Vaccines
    • 9.4.4. Catalent: Zydis Technology
    • 9.4.5. Regional Market Expansion Strategy
  • 9.5. Charles River Laboratories
    • 9.5.1. Recent Financial Performance, 2011-2017
    • 9.5.2. Financial Performance by Segment, 2012-2018
    • 9.5.3. Vaccine Manufacturing Services
    • 9.5.4. Charles River Avian Vaccine Services
    • 9.5.5. Vaccine Manufacturing Expansion
    • 9.5.6. Outlook and Early Stage Restructuring
    • 9.5.7. Partnerships
      • 9.5.7.1. Partnership with AstraZeneca
      • 9.5.7.2. Partnership with Batavia
  • 9.6. IDT Biologika GmbH
  • 9.7. Lonza
    • 9.7.1. Recent Financial Performance
    • 9.7.2. Manufacturing Division Restructuring
  • 9.8. Meridian Life Science
    • 9.8.1. Recent Financial Performance, 2012-2018
  • 9.9. Sigma-Aldrich Fine Chemicals (SAFC) (Merck KGaA)
  • 9.10. SynCo Bio Partners
    • 9.10.1. Recent Developments
      • 9.10.1.1. Expansion of Facilities
      • 9.10.1.2. FDA Approval of Partner Application
  • 9.11. AbbVie Contract Manufacturing
    • 9.11.1. AbbVie Offers Full-Service Contract Manufacturing
    • 9.11.2. Recent Financial Performance: Revenue 2012-2017
    • 9.11.3. Strategic Developments 2017-2018
  • 9.12. Evonik Degussa
    • 9.12.1. API and Drug Delivery Services
  • 9.13. Vetter Pharmaceutical
    • 9.13.1. Financial Performance, 2013-2017
    • 9.13.2. Regional Expansion
  • 9.14. Pfizer CentreOne
    • 9.14.1. Financial Performance, 2013-2018
    • 9.14.2. Strategic Developments 2017-2018
  • 9.15. Nipro Corporation
    • 9.15.1. Contract Manufacturing Capabilities

10. Global Vaccine Contract Manufacturing Market: World Market Trends 2018-2029

  • 10.1. Vaccine Contract Manufacturing Industry Trends
  • 10.2. Strengths
    • 10.2.1. Many Companies Cannot Afford In-house Capabilities
    • 10.2.2. Outsourcing Improves Time to Market
    • 10.2.3. Manufacturers Get Access to Specialised Technologies
    • 10.2.4. Shift Towards Emerging Markets as Favourable Outsourcing Destinations
  • 10.3. Weaknesses
    • 10.3.1. Mass Vaccine Manufacturing Kept In-house
    • 10.3.2. A Highly-Fragmented Vaccine Contract Manufacturing Market
    • 10.3.3. An Unpredictable Supply and Demand Business Model
  • 10.4. Opportunities
    • 10.4.1. Many Vaccines in the Product Pipeline
    • 10.4.2. Emerging Market's Growing Demand for Vaccines
      • 10.4.2.1. Dynamic Change: Emerging Markets are Major Vaccine Developers
    • 10.4.3. Changing World Demographics
  • 10.5. Threats
    • 10.5.1. Post Recession: Biotech Suffer from Severe Cuts in Capital Funding
    • 10.5.2. The Public are Slow to Accept Novel Technologies
    • 10.5.3. Perception of Risk by the Original Vaccine Manufacturers

11. Conclusion

  • 11.1. Overview
  • 11.2. Regulatory and Quality Standards Create High Barriers of Entry
  • 11.3. Emerging Markets Will Show Stronger Growth

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain report evaluation form

List of Tables

  • Table 2.1: Timeline of Key Events in Vaccine Development, c.1000 AD - Present
  • Table 3.1: Vaccine Development Pipeline Using Crucell's AdVac Technology
  • Table 3.2: Benefits and Drawbacks of Using Disposable Technology for Vaccine Production
  • Table 3.3: Companies Providing Disposable Biomanufacturing Platforms/Systems
  • Table 3.4: Some Leading Pre-Filled Syringe Vaccine Products
  • Table 3.5: Prominent Lyophilised Vaccines
  • Table 3.6: Examples of Serum-Free Media for Vaccine Manufacturing
  • Table 4.1: The Global Vaccine Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2018-2029
  • Table 4.2: The Global Vaccine Market: Revenue ($bn) and Market Share by Submarket (%), 2018-2019
  • Table 5.1: The Global Vaccine Contract Manufacturing Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.1: Global Paediatric Vaccines Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.2: Global Adult Vaccines Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.3: Global Influenza Vaccines Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.4: Global Therapeutic Vaccines Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 7.1: Global Downstream Processing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 7.2: Global Fill & Finish Operations Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 7.3: Global Analytical & QC Studies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 7.4: Global Packaging Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 7.5: Global Upstream Processing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 7.6: Global Mammalian Expression Systems Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 7.7: Global Bacterial Expression Systems Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 7.8: Global Yeast Expression Systems Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 7.9: Global Baculovirus/Insect Expression Systems Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 7.10: Global Other Upstream Processing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.1: Leading National Vaccine Contract Manufacturing Markets Forecast: Revenue ($m) and Market Share (%), 2018-2019
  • Table 8.2: North America Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.3: North America Vaccine Contract Manufacturing Market, By Vaccine Type Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.4: North America Vaccine Contract Manufacturing Market by Workflow Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.5: North America Downstream Processing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.6: North America Upstream Processing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.7: US Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.8: Canada Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.9: Europe Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.10: Europe Vaccine Contract Manufacturing Market by Vaccine Type Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.11: Europe Vaccine Contract Manufacturing Market by Workflow Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.12: Europe Downstream Processing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.13: Europe Upstream Processing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.14: Germany Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.15: UK Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.16: France Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.17: Italy Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.18: Spain Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.19: Asia-Pacific Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.20: Asia-Pacific Vaccine Contract Manufacturing Market by Vaccine Type Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.21: Asia-Pacific Vaccine Contract Manufacturing Marke by Workflow Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.22: Asia Pacific Downstream Processing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.23: Asia Pacific Upstream Processing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.24: Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.25: Chinese Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.26: Indian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.27: RoW Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.28: RoW Vaccine Contract Manufacturing Market by Vaccine Type Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.29: RoW Vaccine Contract Manufacturing Market by Workflow Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.30: RoW Downstream Processing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.31: RoW Upstream Processing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.32: Brazilian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.33: Mexican Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.34: Russian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.35: South Africa Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 9.1: Baxter BioPharma Solutions Overview
  • Table 9.2: Baxter BioPharma Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2013-2018
  • Table 9.3: Boehringer Ingelheim Biopharmaceuticals Overview
  • Table 9.4: Boehringer Ingelheim: Biopharmaceuticals Revenue ($m) and Annual Growth Rate (%), 2012-2018
  • Table 9.5: Catalent Overview
  • Table 9.6: Catalent: Revenue($m) and AGR (%), 2012-2018
  • Table 9.7: Charles River Laboratories: Revenue ($m) and AGR (%), 2012-2018
  • Table 9.8: Charles River Laboratories: Newly Revised Reportable Segments
  • Table 9.9: Charles River Laboratories: cGMP Vaccine Manufacturing and Testing Capabilities
  • Table 9.10: Lonza Custom Manufacturing: Revenue ($m) and AGR (%), 2010-2016
  • Table 9.11: Meridian Bioscience: Revenue ($m), AGR (%), 2012-2018
  • Table 9.12: SynCo Bio Partners Capabilities
  • Table 9.13: AbbVie Contract Manufacturing: Details, 2017
  • Table 9.14: Evonik Degussa Details, 2018
  • Table 9.15: Vetter Details, 2017
  • Table 9.16: Vetter Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2013-2017
  • Table 9.17: Pfizer CentreOne Details, 2018
  • Table 9.18: Pfizer CentreSource: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2013-2018
  • Table 9.19: Nipro Pharma Overview
  • Table 9.20: Nipro Pharmaceutical Contract Manufacturing Capabilities: 2011-2017
  • Table 10.1: SWOT Analysis of the Vaccine Contract Manufacturing Market

List of Figures

  • Figure 3.1: Influenza Vaccine Production Using a Cell-Based Manufacturing Method
  • Figure 3.2: Medicago's Product Pipeline
  • Figure 3.3: Novavax' Insect Egg-Based Vaccine Production Process
  • Figure 3.4: Pre-filled Syringes Market: Drivers and Restraints, 2019-2029
  • Figure 4.1: The Global Vaccine Market Forecast: Revenue ($bn), AGR (%) 2018-2029
  • Figure 4.2: The Global Vaccine Market: Market Share by Submarket (%), 2018
  • Figure 5.1: Selected Tasks Outsourced in the Pharmaceutical and Biotech Industry
  • Figure 5.2: Global Vaccine Contract Manufacturing Forecast: Revenue ($m), 2019, 2023 and 2029
  • Figure 5.3: The Global Vaccine Contract Manufacturing Forecast: Revenue ($Mn) and AGR (%), 2018-2029
  • Figure 6.1: Global Vaccine Contract Manufacturing Forecast by Vaccine Type: Revenue ($m), 2018-2029
  • Figure 6.2: Global Vaccine Contract Manufacturing Forecast by Vaccine Type: Market Share (%), 2018-2029
  • Figure 6.3: Global Paediatric Vaccines Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 6.4: Global Adult Vaccines Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 6.5: Global Influenza Vaccines Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 6.6: Global Therapeutic Vaccines Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 7.1: Global Vaccine Contract Manufacturing Forecast by Workflow: Revenue ($m), 2018-2029
  • Figure 7.2: Global Vaccine Contract Manufacturing Forecast, By Workflow: Market Share (%), 2018-2029
  • Figure 7.3: Global Downstream Processing Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 7.4: Global Fill & Finish Operations Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 7.5: Global Analytical & QC Studies Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 7.6: Global Packaging Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 7.7: Global Upstream Processing Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 7.8: Global Mammalian Expression Systems Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 7.9: Global Bacterial Expression Systems Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 7.10: Global Yeast Expression Systems Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 7.11: Global Baculovirus/Insect Expression Systems Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 7.12: Global Other Upstream Processing Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 8.1: The Leading National Vaccine Contract Manufacturing: Market Share (%) by Region, 2018
  • Figure 8.2: North America Vaccine Contract Manufacturing: Market Share (%) by Region, 2018-2029
  • Figure 8.3: U.S. Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 8.4: Canada Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 8.5: Europe Vaccine Contract Manufacturing: Market Share (%) by Region, 2018-2029
  • Figure 8.6: Germany Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 8.7: UK Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 8.8: France Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 8.9: Italy Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 8.10: Spain Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 8.11: Asia-Pacific Vaccine Contract Manufacturing: Market Share (%) by Region, 2018-2029
  • Figure 8.12: Japanese Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 8.13: Chinese Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 8.14: Indian Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 8.15: RoW Vaccine Contract Manufacturing: Market Share (%) by Region, 2018-2029
  • Figure 8.16: Brazilian Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 8.17: Mexican Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 8.18: Russia Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 8.19: South Africa Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 9.1: Baxter BioPharma Manufacturing: Revenue ($m), 2013-2018
  • Figure 9.2: Boehringer Ingelheim: Biopharmaceuticals Revenue ($m) and Annual Growth Rate (%), 2012-2018
  • Figure 9.3: Catalent: Revenue ($m) and AGR (%), 2012-2018
  • Figure 9.4: Catalent Financial Performance by Division: Revenue ($m), 2013-2018
  • Figure 9.5: Charles River Laboratories: Revenue ($m) and AGR (%), 2012-2018
  • Figure 9.6: Lonza Custom Manufacturing: Revenue ($m) and AGR (%), 2010-2016
  • Figure 9.7: Meridian Bioscience: Revenue ($m), and AGR (%), 2012-2018
  • Figure 9.8: Nipro Pharmaceutical Contract Manufacturing Capabilities: Orally Administered Drugs, Injectables, External Preparations, 2011-2017
  • Figure 10.1: Drivers and Restraints for the Vaccine Contract Manufacturing Sector
  • Figure 11.1: The Global Vaccine Contract Manufacturing Market: Market Share by Region (%), 2018, 2023, 2029
  • Figure 11.2: The Global Vaccine Contract Manufacturing: National Market Share (%), 2018 - 2029

COMPANIES LISTED:

  • AbbVie
  • Accugenix
  • AfriVax
  • Alkion Biopharma SAS
  • AmProtein
  • Antigenics, Inc.
  • Arabio
  • Argenta
  • Artelis
  • Astrazeneca
  • ATM Life Sciences
  • ATMI
  • Bacteriological Institute of the Anhaltian Administrative Areas
  • Batavia Bioservices
  • Baxter BioPharma
  • Berna Biotech
  • Bharat Biotech International Limited
  • Binnopharm
  • BioFocus
  • Biovest
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Cadila Pharmaceuticals
  • Calico
  • Catalent
  • Cellexus Limited
  • Charles River Laboratories
  • Chemisch-Pharmazeutisches Laboratorium Ravensburg
  • Colorcon
  • Crucell
  • CSL Biotherapies
  • Daiichi Sankyo Co. Ltd.
  • Elanco
  • Eli Lilly
  • Evonik Degussa
  • FiberCell
  • Gallant Custom Laboratories
  • GE Healthcare
  • GE Wave Biotech
  • GlaxoSmithKline Biologics
  • GSAL
  • GlaxoSmithKline (GSK)
  • Hikma
  • Hyclone
  • IDT Biologika GmbH
  • Intercell Corporation
  • Invitrogen
  • Irvine Scientific
  • Janssen Biotech, Inc. (Janssen)
  • Klocke Group
  • Kuhner
  • LG Life Sciences
  • Lonza
  • Medicago
  • Meissner Filtration
  • Merck & Company
  • Merck Millipore
  • Meridian Bioscience
  • Meridian Life Science
  • MGC Pharma Co.
  • Millipore
  • Mitsubishi Tanabe Pharma
  • MorphoSys
  • Mosquirix
  • MP Biomedicals
  • Mylan
  • Neurocrine Biosciences
  • Nipro Corporation
  • Novartis
  • Novartis Vaccines and Diagnostics
  • Novavax
  • Organon Teknika Corporation
  • Pall Life Sciences
  • PATH
  • Patheon
  • Pfizer
  • Pharmaceutical Base Development Co., Ltd.
  • Pharmacyclics LLC
  • Philip Morris International
  • Pierre-Guerin Biolafitte
  • Protein Sciences Corporation
  • Refine Technology
  • Samsung Bioepis
  • Sanofi
  • Sanofi Pasteur
  • Sartorius Stedim Biotech
  • Scripps Research
  • Shanghai Zhangjiang Biotech
  • ShangPharma Corporation
  • Sigma Aldrich
  • Sigma-Aldrich Fine Chemicals
  • SynCo Bio Partners
  • SynCo Bio Partners (SynCo)
  • Thermo Fisher
  • Vetter Pharmaceutical
  • Vivalis
  • Voyager Therapeutics, Inc.
  • Wave Biotech (GE Healthcare Life Sciences)
  • Wynca
  • Xcellerex (GE Healthcare Life Sciences)
  • ZellWerk
  • Zhejiang Jiang Yuan Tang Biotechnology Corporation

List of Organizations Mentioned in the Report:

  • Centers for Disease Control and Prevention (CDC)
  • Defense Advanced Research Projects Agency (DARPA)
  • European Medicine Agency (EMA)
  • Food and Drug Administration (FDA)
  • Institute Pasteur in Paris
  • Japanese Ministry of Health, Labour and Welfare (MHLW)
  • National Institute of Allergy and Infectious Diseases (NIAID)
Back to Top